US EditionPublished • loading... • Updated
Agilent to acquire Biocare Medical in $950 million all-cash deal
Agilent’s $950 million acquisition of Biocare Medical targets expansion in cancer diagnostics with annual double-digit revenue growth since 2021, boosting its pathology capabilities.
- On Monday, Agilent Technologies agreed to acquire Biocare Medical for $950 million in cash to expand its pathology portfolio and complement IHC and ISH/FISH offerings.
- Since 2021, private-equity stewardship produced sustained double-digit growth at Biocare, sold by an investor group led by Excellere Partners and GHO Capital Partners to Agilent.
- Biocare offers more than 300 specialized antibodies and revenue exceeded $90 million in 2025, Agilent said.
- Agilent said the acquisition is expected to be accretive to top-line growth and margins in year one, and to EPS about a year after close, expected to finish by no later than Agilent's fourth fiscal quarter of 2026.
- As part of Agilent's Life Sciences and Diagnostics Markets Group, Biocare will integrate operationally to expand cancer-diagnostics capabilities and boost development of in vitro diagnostic antibodies.
Insights by Ground AI
13 Articles
13 Articles
Coverage Details
Total News Sources13
Leaning Left2Leaning Right1Center5Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 25%
C 63%
12%
Factuality
To view factuality data please Upgrade to Premium
